invivo@live.com
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Where do you have your rating system posted that you referenced in this post http://investorshub.advfn.com/boards/read_msg.aspx?message_id=57034244
Tia Shen
Do you know how many patients are enrolled in the phase 3 study ?
It looks like the phase 2 results were based on 50 patients. I hope they include more in the phase 3. But at first glance in that population the results are fantastic.Too bad for investors they are private
Ill take a poke
levonorgestrel ?
It is a real company with booming sales one day it will be 30 $ but i cant take the risk it will be 10 first.
I also sent them an email letting them know they were amateur's in their response . How about refuting a lot of what was said . Have your large customer refute the bogus charges. If it goes below 11 i will buy back in
I actually closed my position in premarket after rereading the company's response.No response would have been better but they pointed the finger internally.Who advises some of these companies ? I would rather close out a position with a few hundred loss than watch it tank further. Having said that it is way oversold and should bounce soon.
If you look at all of the short attacks that have been launched even the most believable against CMFO and ONP seemed credible but it appears that all will turn out to be almost completely false. Having said that i think managements response was weak but in the end Rino will be just fine.
GL K
Wow
another early holiday gift
im in
Excellent recap from YMB
http://messages.finance.yahoo.com/Stocks_%28A_to_Z%29/Stocks_A/threadview?m=tm&bn=85843&tid=79&mid=79&tof=2&frt=2
The author has an agressive target - hope he is right. Based on other gaming companies and how hot Macau is - this valuation at $22 may prove right on.
I agree with the author of the posting. With regard to one of the authors points on the oversight at the company's gaming rooms I would add the following points:
1. Macau gets 70% of its tax revenue from gaming and 70% of this from VIP gaming - therefore, they have someone review the gaming room take daily.
2. The Casino is involved in running the room and in verifying the daily winnings in the room as well. So for each room - AERL management, the Casino, and tax authorities sign-off each day on the daily winnings to verify the winnings and taxes to be paid.
These daily checks and monthly settlements with the Casinos add a level of certainty in knowing the numbers are real - no small comfort in the rough and tumble world of investing in the fastest growing economy in the world.
AERL is expected to earn about $38 million (per guidance) in 2010 and based on the recent acquisition may earn $55 million in 2011. Importantly, operating cash flows should be almost equal to net income as the company does not have accounts receivable or inventory. Investments in the business are necessary in the form of cash invested into the "cage" (basically in the gaming room) to drive additional gambling volumes.
With the warrant receipts expected to be over $25 million (per the author) and no more overhang (all warrants gone as of October 28th) - this stock should be ready to run.
Exposure to Macau without the massive cap-ex, debt, and other issues with the large Casinos. A Macau pure-play with diversification operating at three Casinos. Just needs some exposure now after graduating through a significant milestone last week.
Could someone jog my memory on MNTAs trading float ?
Tia
Most companies that are getting ready to apply for approval do not do further studies until post approval . Its risky in so many ways.They already have enough data in my opinion to get approval sometime next year . The only thing another study adds is more risk . You can get Saes even though they have not seen them up until this point.More data can add more questions , they have plenty .It would be better for them to just get bought out . But if you look at their market cap and the potential first 2 years of sales no one will pay to much of a premium over 40$. The other agents will be here in 2 to 3 years.
I am just updating the news flow from the past few months . The company is headed in the right direction
Mr. Timothy Stevens has over 30 years of executive leadership, management, and client service experience with the world's leading law, public accounting, and management consulting firms. Since 2004, Mr. Stevens served as the Executive Director of Saul Ewing LLP, a Philadelphia law firm where he oversaw all aspects of its day to day business operations with a focus on improving the bottom line and supporting the Firm's growth strategy and other key objectives. From 1999 to 2003, he served as the Chief Operating Officer and member of the Management Committee in the Hong Kong and China offices of the international law firm Baker & McKenzie, where he was responsible for all operations (other than client service) for Baker & McKenzie's large Hong Kong/China practice. From 1995 to 1998, Mr. Stevens served in the Chairman's office as the Finance and Administrative Partner of PricewaterhouseCoopers China, the world's largest auditing firm, where he supervised the business plans, office openings and expansions as well as the financial management of the firm. Mr. Stevens graduated from the Clifton College and Bristol University in the United Kingdom. He also received the ACA qualification from the UK Chartered Accountants' Qualification Program in 1974. Mr. Stevens is a licensed CPA in Massachusetts as well as being a Hong Kong FCPA.
http://finance.yahoo.com/news/Deyu-Agriculture-Appoints-prnews-1246654737.html?x=0&.v=101
Deyu Agriculture Acquires Long-Term Land Use Rights to Over 8,700 Acres of Farmland to Expand and Cultivate Ecosystem
http://ih.advfn.com/p.php?pid=nmona&article=44687825&symbol=ECBI
http://ih.advfn.com/p.php?pid=nmona&article=44895143&symbol=ECBI
The notice of effectiveness is a public declaration by the Securities and Exchange Commission that a public company's registration statement has been accepted.
For shares in a public company to trade on the open market they must be registered by the company. These registration statements are reviewed by the Commission for a period of time before approval is given, and this notice marks the successful completion of this review process.
From a blog in August
http://crazyjimsmith.blogspot.com/2010/08/deyu-agriculture-corp-otc-bulletin.html
I bought some shares today
Looks like the filed an S1 to sell around 3 mil shares most at 4.40
One abusive strategy pioneers used was to obtain multiple thirtymonth
stays through the use of so-called “sham” patents, which claim
features peripherally related to the patented drugs, such as metabolites,
intermediates, and packaging features
Financial's Break.... Stock Market Holds....
Stock-Markets / Stock Markets 2010
Oct 16, 2010 - 03:39 AM
By: Jack_Steiman
We have a bear market within a bull market. Unusual but true. The financial sector is in a bear market again as it loses all its critical moving averages. Some stocks in the sector are outright scary such as Capital One Financial Corp. (COF), Bank of America Corporation (BAC), Wells Fargo & Company (WFC), and JPMorgan Chase & Co. (JPM), to name just a few. Take a look at those daily charts if you want to have fear put in to your head. Nasty breakdowns everywhere today in that world of stocks, and on huge volume to confirm those price breakdowns.
The stock market bears will tell the bulls that this is a harbinger of things to come on the dark side. That with the banks breaking down and as a leading sector, the market has no choice but to fall hard over the coming days, weeks and months. I'd be holding back the truth if I said they didn't have at least a point worth talking about. When the financial stocks die, it usually follows that the rest of the market will. However, there is something unique going on here. The rest of the market is acting as if a bull market has kicked in and will not let go. It's the strangest set of circumstances I can ever remember seeing in the stock market. The way the rest of the market held up today is unbelievable.
In the dark days of financial's past, a day like today would have had the Dow down 300-500 points with the Nasdaq down 75-100 points. The Nasdaq held its ground, thanks mostly in part to gains from Apple Inc. (AAPL) as usual, Amazon.com Inc. (AMZN), and Google Inc. (GOOG), which was up 61 points on their earnings report from last night. The technology bull market holding up against the financial bear market. Money simply has moved around. This is normal in good times, but abnormal when the sector leading down in a bear market is the financial's. Interesting times that have a red flag wrapped around it. Even though we held up today, you still have to give great respect to the fact that the financial's are now back in a bear market. I'll be monitoring this very closely day by day for more red flag signals based on market behavior.
There are really only two sectors in a bear market right now. The financial's I've spoken about, but you have to add in how nasty a bear market the school stocks are in. Apollo Group Inc. (APOL) warned the other day and the stock was absolutely annihilated. No guidance will be given for 2011 things are so unclear there. Strayer Education Inc. (STRA), Career Education Corp. (CECO), and all the other players in this sector were taken out and killed as well. Across the board bear market and that's important because many times a stock within a sector can be in a bear market while the others hold up well. Not the case here as all of them are now in bear markets.
Other than that things are good, especially when we focus in on some unexpected sectors. Who would think retail, in this economy, would be in a bull market. But it clearly is, along with goods being transported around the country, which is allowing transports to rock. Commodities and technology are in screaming bull runs. All over the place its bull market after bull market. With the economy supposedly in terrible shape, it's so interesting to see retail stocks reporting such good numbers lately on same store sales. It seems that folks still have that desire to spend to make themselves feel good. As long as that holds up, and there's no sign to the contrary, we will continue to see surprises abound for this market.
When we look at the daily index charts there are inverse head-and-shoulder bullish patterns all over the place. Much of these pattern measurements have played out, thus far, but not totally. The S&P 500 measures to 1220, which is also the April highs. The Dow measures to roughly 11,400. When these patterns break they often make their full measurements. They don't have to, of course, but once well in to their measurements they make it all the way up.
This leads me to believe that through the normal pullback's the market has a decent shot at making it up to 1220 on the S&P 500. The closer we get to this level the more you'll want to start pulling back on your bullishness. It'll feel better and better as we get higher and higher, but if we make it to near S&P 500 1220, you'll want to slow down on your bullish exposure. At the very least you'll see a longer period of lateral consolidation to unwind things if not a large pullback to refresh.
If you watch closely, you'll notice that every time we break through some resistance, that level becomes very strong support on pullbacks. When we finally took out 1131 the market tried twice to give it back only to see it hold when things liked dire. Same held true when we got through 1150, and then once again at 1160. Until this pattern of holding support starts to break you have to keep giving the benefit of the doubt to the bulls.
The bears need to be able to change what exists. The onus is clearly on those bears for now to make the necessary changes to reverse the trend in place. With the 50-day exponential moving average rising on the S&P 500, it'll be at 1131 within a day or so. We all know how strong 1131 support is on price, thus, 1131 will be incredibly tough for the bears to break with the 50-day exponential moving average joining price. Only if we lose 1131 would I start to feel as if the bears are taking back this market. We travel through the maze day by day, and for now things are still bullish overall, but once again, we must remember that red flag coming from the world of the financial's.
Peace,
Jack
http://www.marketoracle.co.uk/Article23545.html
Teva hires Gary Buehler away from FDA
http://www.sfgate.com/cgi-bin/article.cgi?f=/c/a/2010/10/16/BUHK1FTGDK.DTL
Back to Article
Teva hires Gary Buehler away from FDA
Pat Wechsler, Bloomberg News
Sunday, October 17, 2010
Teva Pharmaceutical Industries Ltd., the world's biggest manufacturer of generic drugs, has hired Gary Buehler, the industry's former top regulator.
Buehler will be vice president of regulatory strategic operations at Teva's U.S. unit, Denise Bradley, a spokeswoman for Teva, said Friday. Buehler, who is deputy director of the Food and Drug Administration's Office of Pharmaceutical Science, is scheduled to begin Nov. 1 at Teva, Bradley said.
A 40-year federal employee in public health, Buehler served as the head of FDA's Office of Generic Drugs until March. The agency has struggled to develop a system of fees to fund evaluations of new generic drugs. He is retiring Oct. 23 to take advantage of "an opportunity with the generic drug industry," said Sandy Walsh, an FDA spokeswoman, in an e-mail.
Bradley declined to provide any more details.
Generic-drug-makers have been split over lobbying strategies and regulatory issues since June when Teva, based in Israel, dropped out of the Generic Pharmaceutical Association. Teva joined with U.S. firms Perrigo Co. and Hospira Inc. and Canada's Apotex Inc. earlier this year to form the Generic User Fee Coalition.
What was the reason for the huge volume today ?
Hepatitis C Virus Faces New Weapon From Scientists
http://www.newswise.com/articles/hepatitis-c-virus-faces-new-weapon-from-florida-state-scientists2
Hepatitis C Virus Faces New Weapon From Scientists
Released: 9/29/2010 12:00 PM EDT
Source: Florida State University
Newswise — In recent human trials for a promising new class of drug designed to target the hepatitis C virus (HCV) without shutting down the immune system, some of the HCV strains being treated exhibited signs of drug resistance.
In response, an interdisciplinary team of Florida State University biologists, chemists and biomedical researchers devised a novel genetic screening method that can identify the drug-resistant HCV strains and the molecular-level mechanisms that make them that way –– helping drug developers to tailor specific therapies to circumvent them.
The potentially life-saving technology also works when screening other viruses with drug-resistance issues, notably human immunodeficiency virus (HIV) and influenza.
More than 170 million people worldwide are infected with HCV, which leads to both acute and chronic liver diseases.
“In collaboration with pharmaceutical firm Gilead Sciences and researchers from the University of Heidelberg (Germany), what our research team discovered was how the latest drug for HCV works and what changes in the virus that makes it resistant to this unique therapy,” said Hengli Tang, a Florida State University molecular biologist.
“This is knowledge that is essential to drug developers focused on HCV,” said Tang, “but equally important is that our method, which we call ‘CoFIM’ (Cofactor-independent mutant) screening, can also be applied to other drug targets and other viruses.
“And, since we now understand how this latest class of drug works and what causes resistance to it, we can better select other classes of drugs with distinct mechanisms –– in other words, those that target other parts of the virus –– in order to craft a combination therapy, which is the future of HCV therapy and the key to overcoming drug resistance.”
The groundbreaking research is described in a paper published online in the September 2010 issue of the journal PLoS Pathogens.
Florida State biology doctoral student Feng Yang led the research team. The award-winning scholar earned her Ph.D. in August 2010 and is now a postdoctoral associate at Yale University. Yang designed the CoFIM screening methodology with fellow FSU graduate students, postdoctoral associates and distinguished faculty colleagues –– including Associate Professor Tang; chemistry/biochemistry Professor Timothy M. Logan, director of FSU’s Institute of Molecular Biophysics; and Research Assistant Professor Ewa A. Bienkiewicz, of the FSU College of Medicine, where she directs the Biomedical Proteomics Laboratory.
Driving the team’s development of CoFIM screening was the need to identify key “cellular cofactors” and their mechanisms of action –– a fundamental aspect of virus-host interaction research.
“’Cellular cofactors’ are proteins that normally exist in host cells that have been hijacked by viruses to facilitate viral replication.” Tang said. “They became accomplices to the invading viruses.
“Our research team was the first to show that ‘cyclophilin A’ (CyPA) is an essential cellular cofactor for hepatitis C virus infection and the direct target of a new class of clinical anti-HCV compounds, which include cyclosporine A (CsA)-based drugs that are devoid of immunosuppressive function,” Tang said.
“In addition, we went a step further than other research teams by employing our newly developed CoFIM screening method, which we used to demonstrate not only HCV’s dependence on cellular cofactor cyclophilin A and susceptibility to cyclosporine A drugs but also to uncover the molecular-level regulators that determine those two traits in the virus.”
Those molecular-level regulators are known as “small interfering RNA libraries” –– collections of molecules so named for their size and ability to suppress gene expression. They act to individually suppress every gene in the cell, resulting in different consequences depending upon which gene is suppressed by a given member in the library.
The CoFIM screening method involves inducing or “coaxing” the HCV virus to mutate by itself, in vitro, absent the replication assistance it normally receives from a particular cellular cofactor. Then, CoFIM tracks the changes in the virus’s response both to CsA-based drugs and any other drug designed to inhibit the cofactor.
Funding for the research conducted at Florida State University came in largest part from a $1.4 million grant awarded by the National Institutes of Health (NIH). And, because chronic liver disease caused by HCV can lead to liver cancer, a grant from the American Cancer Society provided additional support.
In addition to now-doctoral alumna Feng Yang and faculty members Hengli Tang, Timothy M. Logan and Ewa A. Bienkiewicz, the Florida State University co-authors of the PLoS Pathogen paper (“A Major Determinant of Cyclophilin Dependence and Cyclosporine Susceptibility of Hepatitis C Virus Identified by a Genetic Approach”) are current biology doctoral students Henry Grise and Stephen Frausto and postdoctoral associates Anita Nag and Jason M. Robotham. Co-authors from the University of Heidelberg Department of Infectious Diseases are Vanesa Madan, Margarita Zayas and Ralf Bartenschlager, and from Gilead Sciences (Foster City, Calif.), Andrew E. Greenstein and Margaret Robinson.
Thanks Viking
because of your posting this.I got back in at 9.37
Thanks Buddy
Why Not own Universal Travel Group(UTA)?
BayCap's CAPS Blog .Why Not own Universal Travel Group(UTA)?
Recs
http://caps.fool.com/Blogs/why-not-own-universal-travel/448918
6
Follow
Share
Report September 20, 2010 – Comments (0) | RELATED TICKERS: UTA , CTRP , LONG
Dear fellow investors,
As you are aware, lately there has been a lot of skepticism around Chinese Small Cap companies. One of Which is a fast growing travel service provider in China. Universal Travel Group (UTA)
Most of you already know the downside associated with it such as fraud, website not being able to take internet orders and payments etc etc. There will always be arguments from the bears.
Yes,while it is true that UTA's services can only be accessed by the local chinese tourist, which raises the eyebrows for many US investor. You can't ignore the fact that the company is indeed a real fast growing operating business.
As someone who has booked a flight,made a reservation of a hotel room, and spoken with the management of the company, I find these bear attacks are dubious compare to the real upside potential of this company.
While the bears only talk about 1 side of the story, I will lay out the other side of the story so the readers can be the judge.
I gotta say, China is probably one of the fastest growing markets. GDP has been growing double digits for the last 10 yrs. So it would make sense for investors to devote as least some capital in that market. US GDP is growing at what?? about 3% and return on money market is even worst. Im sure i don't need to mention how horrible the yield is. Keep in mind that US is pressuring china to appreciate its yuan so it is safe to say that Chinese companies also provide hedging for US currency devaluation.
Here is the link to Chinese GDP movement for the last 30 years
http://www.chinability.com/GDP.htm
http://www.chinability.com/GDP.htm
Now here is the gist of it.
China's tourism sector accounts for 5.5% of GDP in 03 and is expected to reach 11% by 2020. While chinese GDP has been growing at double digits for the past 10 yrs,that makes tourism one of the fastest growing sector in the fastest growing economy.
http://english.peopledaily.com.cn/200308/06/eng20030806_1......
http://english.peopledaily.com.cn/200308/06/eng20030806_121773.shtml
There are 3 major players in this sector that us investors can get exposure to. Elong,Ctrip and of course Universal Travel group. Yes, some of you will argue that Ctrip has more then 50% of the market shares in its online booking business but I can justify paying 52x earnings, for any kind of growth in a business that new comers can easily take a piece of ctrip's market share.
Now, Let's look at Elong . Its similar to UTA, except it has a better web base business. It accounts for around 11 % of total web booking. However, i still dont want to be paying over 100x earnings for a fast growing company.
That leaves us to UTA. Im sure i wont need to be going over its valuation metrics. What some of you should understand is. UTA is brick and motor based business, which means it derives most of its revenue from it's travel agency chain. Most of its sales is from either it's call centers or travel agencies.The company is working on making a better web based business hence the partnership with agoda. However if you look at it carefully, Ctrip will be generating around 450 million revenue give or take and they own around 50% market shares in online booking. So We can safely assume that revenue derived from all of online booking should be around 1 billion US dollars.
So the question is, Does it make sense for UTA to focus more growing its on web-based business to gain local and international market shares or Does it make more sense for UTA to keep acquiring traveling agencies to gain brand awareness and boarder it's market share in the 1.44 trillion RMB dollar inbound and outbound traveling sector??
http://www.nytimes.com/2010/02/02/business/global/0......
http://www.nytimes.com/2010/02/02/business/global/02tourist.html?_r=1
Im sure there are risk related to investing in Universal Travel Group but i just cant ignore the upside associated with it. Im not saying to dump your whole portfolio into this company but if you want to gain some exposure into the fastest growing sector in the fastest growing economy, UTA can meet your appetite.
In conclusion, I believe UTA should have a small place in everyone's portfolio. That is if they want to gain some exposure in the growth of china.
Below is the link for my visit to UTA's call center which is a blog written by a friend of mine.
http://caps.fool.com/Blogs/a-quotrealquot-visit-to/447974
http://caps.fool.com/Blogs/a-quotrealquot-visit-to/447974
Best Regards,
Wai Lam
Duplicate post sorry
Look at the short pressure coming in . Quite frankly if i were short CCME i would flip it to a stock like NEP. I made the mistake of thinking everyone who wanted out sold but remember shorts are now getting their first real chance at the carcass
This is not a bad place to enter the stock. I thought the same on friday..I do not want to hold because this stock could go below 4 again. It probably wont but i think some shorts have piled on. Remember when the other China stocks were being shorted to the gills , Nep was not trading. I wish i would have remembered that on Friday. There are just to many other plays like CCME and UTA TSTC that look like the have put in a solid floor.The trading ground is still shaky with NEP
I took some losses. Sold out . I do not like this price action
GLTA
Cold Hard Facts
Cash (MRQ) 45.67 mill
NO DEBT
Revenue Growth(Y/Y)144.09%
P/E 3.41
Price/Sales 1.30
Price/Book 1.60
No evidence exists to indicate that funds were misappropriated, stolen or otherwise misused by anyone. Furthermore, the JLA report did not find any material misstatements in the Company's prior financial reports filed with the SEC
The revenue from Tiancheng is expected to finance the future drilling and production of crude oil for the Company's oil production division.
Minimum company value 7 $
This is before any future announcements on aquistions or new drilling .Remember the weather held back production and drilling.
That is currently in the past
~$3/share for the company's year-end 2010e proved reserves (valued at ~$20.50/Bbl),
~$2/share for its drilling unit (valued at 2.5x EBITDA), and ~$2/share of net cash
Solid repost( not mine ) from the dark board
Opportunities Knocking, Hard
No one is giving 100 per cent guarantees but let's look at the information that is available before writting off this company. Are they in the right business? A no brainer, China needs all the oil it can get and will continue to need it for the forseeable future. No need to worry about a glut problem. Timely and accurate reporting of finances. We're just clearing that bunker so I'm reasonably confident that the numbers the company just reported are accurate. On that topic bear in mind that it wasn't misappropriation of funds, stealing or some other skullduggery that caused the problem rather it was the way the warrants and oilfield depreciation was accounted for. No small matter but correctable and hopefully already corrected. It is my opinion that the shorts and thier friends in the financial press are creating much of the bruhaha that is driving down many of the Chinese micros. Sloppy financials no doubt are part of the mix but the shorts blow it out of all proportion and kill the stocks. I say apportunity is knocking. What do we know? The stock was trading at $10.07 on Jan 4th, today we're at $4.70. For the first 6 months of 10 the company had production revenues of 32 million as opposed to 20.9 in 09. Additionally the recently aquired drilling division recorded 24.6 in revenues for 10, absent in 09. Cash on hand growing, 34.2 million on March 31st 10 to 46.5 million on June30th 10. I really love it when the bottom line growth keeps abreast of the top line. The downside for this period is that they haven't drilled any new wells. The upside is that they are financially positioned to make aquisitions, something that the company has hinted at. Owning our own drilling company should place us in the cat bird seat, in case you're not familair with the term, it's a good place to be. I bought in after the company started trading. At this price I will continue to add. There are many Chinese micros going for four to eight times earnings with CAGR's of thirty to fifty per cent or higher. They are mostly thinly traded therefore easy to manipulate. One day this will pass and many of us will be saying , how could I have not bought them when they were so cheap, plenty of cash on hand, 3 to 4 times earnings, top and bottom line growth of forty or fifty per cent. Knock Knock. In the previous post they asked how high, I could see it at $15 as soon as the financial press knocks off the distortions regarding the Chinese micros financials. On that subject, can anyone cite examples of outright fraud or theft on the part of management. I'm sure that it's happened but not to the degree that the press is inferring.
http://messages.finance.yahoo.com/Stocks_%28A_to_Z%29/Stocks_C/threadview?m=tm&bn=96240&tid=17207&mid=17207&tof=1&frt=2
I bought in yesterday with a big chunk of my portfolio for several reasons.But i don't think it is racing back to 9$ quickly until sentiment changes.That being said i made some price comparisons to another one of my China holdings that has been hit hard.
Since the beginning of May CCME is down 40% (crazy )
Nep is down 52 % . I am hoping for a minimum 30% gain in NEP in the next month and a minimum 25 % gain in CCME. Once sentiment changes both stock are 70% gainers by year end.
Smart Money's Top 9 Biotech Picks
http://seekingalpha.com/article/225490-smart-money-s-top-9-biotech-picks?source=yahoo
The following is the top 9 biotech stocks in terms of institutional inflows over the last 3 months. For each stock, we'll list the change in institutional ownership over the last 3 months.
To give perspective on current investor sentiment, we'll also include short float and performance data.
We won't go into details about the drugs being developed by each company. The goal here is to give you a starting point based on a quantitative screen.
Short float data sourced from Finviz, institutional trading data sourced from Reuters.com.
The list has been sorted by change in institutional ownership.
1. Crucell NV (CRXL): Market cap of $1,674B. Institutional investors, who own 10.12% of the company, currently owns 8,244,942 shares vs. 5,109,700 shares held 3 months ago (+61.36% change). Short float at 0.87%, which implies a short ratio of 7.22 days. The stock has lost -13.1% over the last year.
2. Sequenom Inc. (SQNM): Market cap of $500M. Institutional investors, who own 54.68% of the company, currently owns 41,032,190 shares vs. 26,622,509 shares held 3 months ago (+54.13% change). Short float at 26.07%, which implies a short ratio of 8.28 days. The stock has gained 15.83% over the last year.
3. Clinical Data, Inc. (CLDA): Market cap of $492M. Institutional investors, who own 33.99% of the company, currently owns 10,147,220 shares vs. 7,364,396 shares held 3 months ago (+37.79% change). Short float at 13.3%, which implies a short ratio of 18.17 days. The stock has gained 6.74% over the last year.
4. NPS Pharmaceuticals, Inc. (NPSP): Market cap of $390M. Institutional investors, who own 87.9% of the company, currently owns 51,834,805 shares vs. 38,774,483 shares held 3 months ago (+33.68% change). Short float at 4.13%, which implies a short ratio of 8.28 days. The stock has gained 41.24% over the last year.
5. Immunogen Inc. (IMGN): Market cap of $383M. Institutional investors, who own 76.79% of the company, currently owns 52,178,352 shares vs. 41,618,616 shares held 3 months ago (+25.37% change). Short float at 8.92%, which implies a short ratio of 7.38 days. The stock has lost -28.1% over the last year.
6. Momenta Pharmaceuticals Inc. (MNTA): Market cap of $687M. Institutional investors, who own 83.16% of the company, currently owns 37,652,025 shares vs. 31,665,207 shares held 3 months ago (+18.91% change). Short float at 13.55%, which implies a short ratio of 3.93 days. The stock has gained 43.93% over the last year.
7. Questcor Pharmaceuticals, Inc. (QCOR): Market cap of $635M. Institutional investors, who own 81.56% of the company, currently owns 50,655,431 shares vs. 46,456,741 shares held 3 months ago (+9.04% change). Short float at 7.27%, which implies a short ratio of 6.03 days. The stock has gained 60.69% over the last year.
8. Amylin Pharmaceuticals, Inc. (AMLN): Market cap of $3,072B. Institutional investors, who own 98.73% of the company, currently owns 141,850,211 shares vs. 132,214,769 shares held 3 months ago (+7.29% change). Short float at 11.46%, which implies a short ratio of 7.88 days. The stock has gained 56.63% over the last year.
9. Emergent BioSolutions, Inc. (EBS): Market cap of $579M. Institutional investors, who own 55.14% of the company, currently owns 17,263,457 shares vs. 16,185,975 shares held 3 months ago (+6.66% change). Short float at 5.15%, which implies a short ratio of 3.72 days. The stock has lost -6.28% over the last year.
Disclosure: No positions
Back in @ 7.9
2 glasses of water before each meal
http://www.sciencedaily.com/releases/2010/08/100823142929.htm
Quote:
--------------------------------------------------------------------------------
This should be a game changer tomorrow morning.
--------------------------------------------------------------------------------
I doubt it. There was never any bona fide evidence that Sandoz was not taking a significant Lovenox share in the hospital setting, so Wheeler’s comment on today’s webcast, although bullish, is not exactly surprising.
No afterhour movement in price
But isn't the low volume Copaxone considered a new drug ? So the approval process is much more difficult .
I seem to remember posters here saying the Hospital uptake would be a more difficult barrier and i thought they gave some specific examples of large companies that had not begun to use Enox. I guess that was dismissed today . This guy is very credible unlike a lot of small Bio tech companies who pump at every chance.
What a Moron for an analyst ?
Why cant TEVA get a new drug approved before MNTA can get the generic copax approved.
What idiots
Enox Hospital uptake has been equal to retail uptake.
Did i hear that correctly
unscientific
Did you admit it !
Go ahead ill absolutely give you the last word .
This is my last post on this point but by you posting the word unscientific i know in my heart that you have admitted you were wrong.So no need for me to post further and my respect for you is back up to its previous level
Signing off for tonight
Ciao